drugset / Trial / NCT04478071
Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)
Phase 2
Completed
448 enrolled
The University of Texas Health Science Center, Houston
Akebia Therapeutics · collabUnited States Department of Defense · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy of vadadustat for the prevention and treatment of acute respiratory distress syndrome (ARDS) in hospitalized patients with Coronavirus Disease 2019 (COVID-19).
Timeline
- Start
- 2020-08-22
- Primary completion
- 2022-03-07
- Completion
- 2022-03-25
Outcome
Missed primary endpoint
registry analysis (superiority test); Vadadustat vs Placebo; Risk Difference (RD) -0.036 (95% CI -0.084 to 0.009) NCT04478071 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vadadustat | Small molecule | — | — |